Motilium® (domperidone): New recommendations to minimise cardiac risks

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 4 August 2015

Description:

The NPCB would like to alert healthcare professionals of restrictions to the use of domperidone to minimise the risk of cardiac adverse effects. The indication of domperidone has been tightened, the maximum daily dose restricted to 40mg/day, and new contraindications have been added.Domperidone should be used at the lowest effective dose for the shortest possible duration. The DCAhas issued a directive for all products containing domperidone to update their package inserts with information regarding this safety issue. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by Janssen, a division of Johnson & Johnson Sdn. Bhd., in agreement with NPCB.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA